Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2012

01-01-2012 | Research Paper

The involvement of NK cell activation following intranasal administration of CpG DNA lipoplex in the prevention of pulmonary metastasis and peritoneal dissemination in mice

Authors: Shuwen Zhou, Shigeru Kawakami, Yuriko Higuchi, Fumiyoshi Yamashita, Mitsuru Hashida

Published in: Clinical & Experimental Metastasis | Issue 1/2012

Login to get access

Abstract

Synthetic oligodeoxynucleotides containing CpG motifs (CpG DNA) can activate immunocompetent cells, which may possess antitumor activity. Previously, we found that when the cationic liposomes complexes formed with CpG DNA (CpG DNA lipoplex) were administered intranasally, they could prevent pulmonary metastasis in mice. However, the mechanisms underlying this process are unknown. In the present study, we show that natural killer (NK) cells play an important role in preventing pulmonary metastasis and peritoneal dissemination in a mouse model of metastatic disease. Further, in vitro, the NK cells obtained from mice treated with CpG DNA lipoplex showed higher cytotoxicity compared with untreated mice and in vivo, depletion of NK cells (achieved through injection of rabbit anti-asialo GM1 serum), abolished the inhibitory effect of CpG DNA lipoplex on pulmonary metastasis and peritoneal dissemination. In contrast, macrophage elimination did not disrupt the effects of the CpG DNA lipoplex. These results suggest that intranasal administration of CpG DNA lipoplex could prevent pulmonary metastasis and peritoneal dissemination by activating NK cells.
Literature
1.
Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760PubMedCrossRef
2.
Krieg AM (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27(2):161–167PubMedCrossRef
3.
Nierkens S, den Brok MH, Roelofsen T et al (2009) Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One 4(12):e8368PubMedCrossRef
4.
Kuramoto Y, Kawakami S, Zhou S et al (2008) Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. J Control Release 126(3):274–280PubMedCrossRef
5.
Kuramoto Y, Kawakami S, Zhou S et al (2009) Mannosylated cationic liposomes/CpG DNA complex for the treatment of hepatic metastasis after intravenous administration in mice. J Pharm Sci 98(3):1193–1197PubMedCrossRef
6.
Ugwoke MI, Agu RU, Verbeke N et al (2005) Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 57(11):1640–1665PubMedCrossRef
7.
8.
Zhou S, Kawakami S, Yamashita F et al (2010) Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Lett 287(1):75–81PubMedCrossRef
9.
Schantz SP, Brown BW, Lira E et al (1987) Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer. Cancer Immunol Immunother 25:141–148PubMedCrossRef
10.
Vivier E, Tomasello E, Baratin M et al (2008) Functions of natural killer cells. Nat Immunol 9(5):503–510PubMedCrossRef
11.
12.
Moldoveanu Z, Love-Homan L, Huang WQ et al (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16(11–12):1216–1224PubMedCrossRef
13.
Pum PB, Bhat AA, Mohan T et al (2009) Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. Int Immunopharmacol 9(4):468–477CrossRef
14.
Corbctt TH, Griswold Jr, Robcrts BJ et al (1975) Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays with a note on carcinogen structure. Cancer Res 35(9):2434–2439
15.
Hyoudou K, Nishikawa M, Umeyama Y et al (2004) Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells. Clin Cancer Res 10(22):7685–7691PubMedCrossRef
16.
Kawakami S, Sato A, Nishikawa M et al (2000) Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther 7(4):292–299PubMedCrossRef
17.
Kuramoto Y, Nishikawa M, Hyoudou K et al (2006) Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J Control Release 115(2):226–233PubMedCrossRef
18.
Wijagkanalan W, Kawakami S, Takenaga M et al (2008) Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J Control Release 125(2):121–130PubMedCrossRef
19.
Yoon TJ, Kim TJ, Lee H et al (2007) Anti-tumor metastatic activity of beta-glucan purified from mutated Saccharomyces cerevisiae. Int Immunopharmacol 8(1):36–42PubMedCrossRef
20.
Saiki I, Saito S, Fujita C et al (1998) Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues. Vaccine 6:238–244
21.
Yoon TJ, Yoo YC, Lee SW et al (2004) Anti-metastatic activity of Acanthopanax senticosus extract and its possible immunological mechanism of action. J Ethnopharmacol 93(2–3):247–253PubMedCrossRef
22.
Yoon TJ, Yoo YC, Kang TB et al (1998) Prophylactic effect of Korean mistletoe (Viscum album coloratum) extract on tumor metastasis is mediated by enhancement of NK cell activity. Int J Immunopharmacol 20(4–5):163–172PubMedCrossRef
23.
Kitchens WH, Chase CM, Uehara S et al (2007) Macrophage depletion suppresses cardiac allograft vasculopathy in mice. Am J Transplant 7(12):2675–2682PubMedCrossRef
24.
Gregoire C, Chasson L, Luci C et al (2007) The trafficking of natural killer cells. Immunol Rev 220:169–182PubMedCrossRef
25.
26.
Bahjat KS, Prell RA, Allen HE et al (2007) Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease. J Immunol 179(11):7376–7384PubMed
27.
Sivori S, Falco M, Della Chiesa M et al (2004) CpG and double-stranded RNA trigger human NK cells by toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 101(27):10116–10121PubMedCrossRef
28.
Paget C, Bialecki E, Fontaine J et al (2009) Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides. J Immunol 182(4):1846–1853PubMedCrossRef
29.
Lysaght J, Jarnicki AG, Mills KH (2007) Reciprocal effects of Th1 and Treg cell inducing pathogen-associated immunomodulatory molecules on anti-tumor immunity. Cancer Immunol Immunother 56(9):1367–1379PubMedCrossRef
30.
Shindo H, Ogura T, Masuno T et al (1985) Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice. Cancer Immunol Immunother 20(2):145–15025PubMedCrossRef
31.
Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211–217PubMedCrossRef
32.
Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796(1):11–18PubMed
33.
Zeisberger SM, Odermatt B, Marty C et al (2006) Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95:272–281PubMedCrossRef
34.
Suzuki K, Suda T, Naito T et al (2005) Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. Am J Respir Crit Care Med 171(7):707–713PubMedCrossRef
Metadata
Title
The involvement of NK cell activation following intranasal administration of CpG DNA lipoplex in the prevention of pulmonary metastasis and peritoneal dissemination in mice
Authors
Shuwen Zhou
Shigeru Kawakami
Yuriko Higuchi
Fumiyoshi Yamashita
Mitsuru Hashida
Publication date
01-01-2012
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 1/2012
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-011-9429-1

Other articles of this Issue 1/2012

Clinical & Experimental Metastasis 1/2012 Go to the issue

Research Paper

Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma

Research Paper

Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI

Research Paper

CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion

Research Paper

Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance

Research Paper

Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival

Research Paper

Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits